FT Pharma 2013: Teva’s acting CEO says it has “a very strong and clear strategy”
Eyal Desheh, acting president and chief executive of the world’s largest generics maker Teva (NYSE: TEVA), told delegates at the Financial Times Global Pharmaceutical & Biotechnology Conference in London yesterday that the company is “prepared” for the patent loss of Copaxone (glatiramer acetate) next year.
Global revenues for the leading multiple sclerosis therapy were $1.05 billion in the company’s third quarter results, an increase of 1% compared to the third quarter of 2012.
“Copaxone is of the most wonderful drugs ever invented for MS. But like every product the patent will come to an end,” said Mr Desheh. “Teva is prepared.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze